MedTrace Logo

Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis

NCT03898635 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-04-02

No results posted yet for this study

Summary

Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.

Conditions

  • Tuberculous Meningitis

Interventions

DRUG

Linezolid

To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2019-05-01
Completion
2019-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03898635 on ClinicalTrials.gov